Hasan Erdogan

Hasan Erdogan

Namil kemal University, Turkey

Title: Protection from side effects of anticancer drugs


Hasan Erdogan has completed his MD at Firat University, Turkey and received PhD in Physiology at Inonu University, School of Medicine. He is an Associated Dean of Namik Kemal University, Faculty of Medicine. He is also a Lecturer at the Department of Physiology of Basic Medical Sciences. He has published more than 25 papers in reputed journals which have been cited more than 680 times.


Anticancer drugs have severe side eff ects and its clinical usage for cancer therapy is limited by its toxicity. It is important to prevent the side eff ects of anticancer drugs in cancer chemotherapy. Our studies have shown that there are some agents that mostly diminish the side eff ects of anticancer drugs. For instance, an antineoplastic agent bleomycin challenge provokes severe pulmonary fi brosis. Melatonin and Ginkgo bilobaare are highly promising agents in protecting bleomycin-induced lung fi brosis. Most studies have shown that doxorubicin -an anthracycline antibiotic with broad activity against haematological malignancies- has limited clinical usage owing to its cardiotoxicity. Erdosteine and Caff eic Acid Phenethyl Ester protect the myocardial tissue from doxorubicin induced cardiotoxicity. Which mechanisms are underlying the useful eff ects of those agents? Antioxidant eff ects, anti-apoptotic pathway, anti-angiogenic mechanism, so on. It is more important to determine which the most protective agent is against toxicity of anticancer drug. Additionally, it is important to know which types of cancers are protected by those agents.